December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about atopic dermatitis

Recent news which mentions atopic dermatitis

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Tickers JNJ NEWS SWAV
Tags atopic dermatitis JNJ Benzinga
From Benzinga
Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis
Tickers LLY
Tags Market News Large Cap LLY
From Benzinga
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
Tickers VYNE
Tags Penny Stocks Biotech News
From Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
Tickers REGN SNY
Tags Health Care Briefs SNY
From Benzinga
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
Tickers ASLN
Tags General Market News News
From Benzinga
FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older
Tickers ABBV
Tags Guidance Briefs Health Care
From Benzinga
EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa
Tickers HOTH
Tags Health Care Biotech Penny Stocks
From Benzinga
Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint
Tickers CNTB
Tags Market News News General
From Benzinga
AbbVie Presents New Upadacitinib Data In Atopic Dermatitis
Tickers ABBV
Tags atopic dermatitis ABBV General
From Benzinga
Pfizers' JAK Inhibitor Approved In Japan For Atopic Dermatitis
Tickers PFE
Tags Benzinga General atopic dermatitis
From Benzinga
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
Tickers ASLN
Tags Health Care Trading Ideas Briefs
From Benzinga
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
Tickers INCY
Tags atopic dermatitis Benzinga Trading Ideas
From Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Tickers PFE REGN SNY
Tags REGN Biotech News
From Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
Tickers REGN SNY
Tags Market News Phase 3 Results News
From Benzinga
Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials
Tickers LLY
Tags Market News LLY News
From Benzinga
VYNE Therapeutics Stock Drops On Potential Sale Of Topical Minocycline Franchise
Tickers VYNE
Tags M&A Penny Stocks Biotech
From Benzinga
FDA Will Not Meet Goal Dates For Pfizer's Xeljanz, Abrocitinib Applications
Tickers PFE
Tags Briefs Biotech FDA
From Benzinga
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
Tickers ABBV INCY LLY
Tags FDA Health Care Biotech
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.